Sir -The recent papeer by Davis et al. (British Journal of Cancer (1992), 66, 777-780) presents evidence that drugs used in the therapy of inflammatory bowel disease (IBD) may be co-carcinogenic. The study reported was based on the exposure of rats to a combination of the carcinogen dimethylhydrazine (DMH) and doses of dugs that are in excess of those used for clinical maintenance of IBD. The explanation offered for some of the results, in particular those of sulphasalazine, is not compatible with the model employed.
The DMH model is an attractive one. Dimethylhydrazine undergoes conjugation with subsequent secretion into the bile and the liberation of the free N-hydroxy compound by the colonic flora (Enker et al., 1976) , thus mimicking the course of potential dietary carcinogens. Neoplastic change occurs through the formation and persistance of methylated purines (Cooper et al., 1978) . In human sporadic colon adenocarcinoma, however, the evidence points towards DNA hypomethylation as the significant factor in oncogene expression (Feinberg & Vogelstein, 1983) .
The authors suggest that sulphasalazine may be co-carcinogenic on account of the anti-folate nature of its sulphonamide moiety. The most likely mechanism for such an influence would be through reduced levels of the one-carbon donor S-Adenosylmethionine, or, through reduced levels of 5,10-Methylenetetrahydrofolate required for thymidine synthase activity. As DNA hypomethylation may result from either of these circumstances a DMH model does not provide a sound support for the authors' conclusion.
The implication of the anti-folate action of sulphasalazine is an extension of the theory that localised tissue folate deficiency may underly carcinogenesis. Such a state has been postulated to be a factor in the development of colonic dysplasia (Lashner et al., 1989) ; cervical dysplasia (Butterworth et al., 1992) and bronchial squamous metaplasia (Heimburger et al., 1988 ZO The Netherlands.
